.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Updates on Biomarker-Directed Therapy for Solid Tumors: Focus on NTRK, RET, and NRG-1

EP. 1: Importance of Biomarker Testing for Solid Tumors

March 31st 2021

Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.

EP. 2: Key Considerations for Biomarker Testing

March 31st 2021

Jyoti Patel, MD, FASCO, discusses the pros and cons of tissue versus blood for molecular testing of solid tumors.

EP. 3: Pan-Tumor Biomarker Testing in Oncology

April 7th 2021

A panel of oncology experts in lung, thyroid, and sarcomatous tumors discuss the role and impact of pan-tumor biomarker testing.

EP. 4: Companion Diagnostics in Oncology for Solid Tumors

April 7th 2021

Experts in oncology provide their insights on the use of companion diagnostics in the treatment of solid tumors.

EP. 5: Solid Tumors: Unmet Needs Related to Biomarker-Driven Therapy

April 14th 2021

Dr Mark Socinski and panel discuss the challenges and unmet meets of biomarker-driven therapy across solid tumor types.

EP. 6: NRTK Fusions in Oncology

April 14th 2021

Dr Lori Wirth describes the importance and implications of testing for NRTK fusions in patients with solid tumors.

EP. 7: Treatment Options for NRTK Fusion–Positive Solid Tumors

April 21st 2021

Benjamin Levy, MD, reviews the available treatment options for patients whose tumors harbor NRTK fusions.

EP. 8: TRK Fusion Inhibitors in Tumor-Agnostic Clinical Trials

April 21st 2021

Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.